Carvykti Meets Another Regulatory Milestone; LB1901’s FDA Clinical Hold Lifted; Legend Q1 2022 Earnings Summary
On Wednesday, June 1, Legend released their Q1 2022 results (press release) highlighting Carvykti’s (cilta-cel; BCMA CAR-T) recent European Commission (EC) conditional marketing authorization in ≥4L r/r MM. Additionally, management confirmed that the FDA lifted the clinical hold on LB1901’s (LCAR-T2C; autologous CD4 CAR-T) Ph1 trial in r/r TCL. Below, Celltelligence provides insights on Carvykti’s EC approval, while discussing LB1901’s FDA clinical hold lift.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.